Company announcements · 16/10/20261 min read
Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models
Summary
Actinium Pharmaceuticals will present oral and poster presentations at EANM 2026, highlighting the antitumor activity of ATNM-400 across various cancer models, including lung, colorectal, and ovarian cancer.
Original source language: PR NewswireOpen original release →